In last trading session, Gilead Sciences Inc. (NASDAQ:GILD) saw 11.14 million shares changing hands with its beta currently measuring 0.39. Company’s recent per share price level of $75.67 trading at -$1.69 or -2.18% at ring of the bell on the day assigns it a market valuation of $91.73B. That closing price of GILD’s stock is at a discount of -18.59% from its 52-week high price of $89.74 and is indicating a premium of 18.81% from its 52-week low price of $61.44. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 5.83 million shares which gives us an average trading volume of 5.63 million if we extend that period to 3-months.
For Gilead Sciences Inc. (GILD), analysts’ consensus is at an average recommendation of an Overweight while assigning it a mean rating of 2.50. Splitting up the data highlights that, out of 29 analysts covering the stock, 1 rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 14 suggested the stock as a Hold whereas 13 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of $1.91 in the current quarter.
Gilead Sciences Inc. (NASDAQ:GILD) trade information
Upright in the red during last session for losing -2.18%, in the last five days GILD remained trading in the red while hitting it’s week-highest on Thursday, 09/14/23 when the stock touched $75.67 price level, adding 2.65% to its value on the day. Gilead Sciences Inc.’s shares saw a change of -11.86% in year-to-date performance and have moved -0.43% in past 5-day. Gilead Sciences Inc. (NASDAQ:GILD) showed a performance of -2.99% in past 30-days. Number of shares sold short was 18.25 million shares which calculate 3.46 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $90.86 to the stock, which implies a rise of 16.72% to its current value. Analysts have been projecting $71.00 as a low price target for the stock while placing it at a high target of $116.00. It follows that stock’s current price would drop -53.3% in reaching the projected high whereas dropping to the targeted low would mean a gain of 6.17% for stock’s current value.
Gilead Sciences Inc. (GILD) estimates and forecasts
Statistics highlight that Gilead Sciences Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -5.23% of value to its shares in past 6 months, showing an annual growth rate of -8.54% while that of industry is 12.00. Apart from that, the company came lowering its revenue forecast for fiscal year 2023. The company is estimating its revenue growth to increase by 0.50% in the current quarter and calculating 19.80% increase in the next quarter. This year revenue growth is estimated to fall -1.50% from the last financial year’s standing.
20 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $6.81 billion for the same. And 19 analysts are in estimates of company making revenue of $7.12 billion in the next quarter that will end on Dec 2023. Company posted $6.12 billion and $7.39 billion of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 11.20% while estimating it to be -3.60% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -13.90% during past 5 years. In 2023, company’s earnings growth rate is likely to be around -26.20% while estimates for its earnings growth in next 5 years are of 4.43%.
Gilead Sciences Inc. is more likely to be releasing its next quarterly report between October 25 and October 30 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Gilead Sciences Inc. (NASDAQ:GILD)’s Major holders
Insiders are in possession of 0.10% of company’s total shares while institution are holding 86.84 percent of that, with stock having share float percentage of 86.93%. Investors also watch the number of corporate investors in a company very closely, which is 86.84% institutions for Gilead Sciences Inc. that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at GILD for having 126.19 million shares of worth $9.73 billion. And as of Jun 29, 2023, it was holding 10.13% of the company’s outstanding shares.
The second largest institutional holder is Vanguard Group Inc, which was holding about 113.37 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 9.10% of outstanding shares, having a total worth of $8.74 billion.
On the other hand, Vanguard Total Stock Market Index Fund and Income Fund of America Inc are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 38.97 million shares of worth $3.0 billion or 3.13% of the total outstanding shares. The later fund manager was in possession of 33.74 million shares on Jun 29, 2023, making its stake of worth around $2.6 billion in the company or a holder of 2.71% of company’s stock.